Navigation Links
Clinical trials demonstrate effective weight loss strategies for obese and overweight adults
Date:10/9/2010

CHICAGO -- Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.

According to background information in the papers, obesity is among the most significant public health problems of the 21st century and the prevalence of obesity has been rapidly rising for the past three decades, especially among African American women. National statistics indicate that the prevalence for overweight and obesity combined (having a body mass index of 25 or greater) is 68 percent of the population. Both papers note the increased risk of numerous other medical problems for people who are overweight or obese, including diabetes and high blood pressure. The authors also point out the lack of scientific evidence for most weight loss programs or evidence-based treatment guidelines, particularly for severe obesity.

In a one-year intensive lifestyle intervention study of diet and physical activity, Bret H. Goodpaster, Ph.D., from the University of Pittsburgh School of Medicine and colleagues, randomized a group of 130 severely obese adult individuals without diabetes in two groups to assess weight loss for a period of one year. One group was randomized to diet and physical activity for the entire 12 months, while the other group had the identical dietary intervention, but with physical activity delayed for six months. The study was conducted from February 2007 with follow-up through April 2010.

"To facilitate dietary compliance and improve weight loss, liquid and pre-packaged meal replacements were provided at no cost for all but one meal per day during months one through three and for only one meal replacement per day during months four through six of the intervention," the authors report. The physical activity component included brisk walking up to 60 minutes, five days a week. Participants were provided with a pedometer and encouraged to walk at least 10,000 steps a day. Small financial incentives for adherence to the behavioral goals of the intervention were also provided. The participants received a combination of group, individual and telephone contacts as part of the lifestyle intervention.

"Of 130 participants randomized, 101 (78 percent) completed the 12-month follow-up assessments," the authors state. The group that started with the diet and physical activity lost more weight in the first six months than the delayed-activity group (about 24 pounds as compared to 18 pounds). However, the authors report that weight loss at 12 months was about the same in the two groups (almost 27 pounds versus about 22 pounds). "Waist circumference, visceral abdominal fat, hepatic (liver) fat content, blood pressure and insulin resistance were all reduced in both groups," according to the authors.

"In conclusion, intensive lifestyle interventions using a behavior-based approach can result in clinically significant and meaningful weight loss and improvements in cardiometabolic risk factors in severely obese persons. It is also clear that physical activity should be incorporated early in any dietary restriction approach to induce weight loss and to reduce hepatic steatosis [fatty liver] and abdominal fat. Our data make a strong case that serious consideration should be given by health care systems to incorporating more intensive lifestyle interventions similar to those used in our study. Additional studies are clearly needed to determine long-term efficacy and cost-effectiveness of such approaches."

(JAMA. 2010;304[16]: doi:10.1001/JAMA.2010.1505. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: This study was funded by the Commonwealth of Pennsylvania Department of Health. Co-author Jolene Brown, M.D., was supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: The State of Obesity and Obesity Research

"Class II obesity (body mass index [BMI] of more than 35) and class III obesity (BMI of 40 or more) is a prevalent condition that adversely affects health," according to Donna H. Ryan, M.D. of Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, and Robert Kushner, M.D., M.S., of Northwestern University Feinberg School of Medicine, Chicago, in an accompanying editorial.

"Severe obesity is a prevalent public health problem, disproportionately affecting women and minorities. There is still much to learn about the mechanisms underlying differing risk and treatment outcomes between populations. Optimal treatment approaches for class II and class III obesity are underexplored, while payment approaches for interventions known to work have yet to be adopted."

"Additional rigorous research, such as the clinical trial by Goodpaster et al, are needed to unravel the causes, identify prevention strategies, and develop the best treatments for obesity," they conclude.

(JAMA.2010; 304 [16]: doi:10.1001/JAMA.2010.1531. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Please see the article for additional information, author contributions and affiliations, financial disclosures, etc.


'/>"/>

Contact: Amy Dugas Rose
DugasAK@upmc.edu
412-586-9776
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. U-M receives NIH, FDA grant to study adaptive clinical trial designs
2. MJFF announces over $10 million in funding for clinical and pre-clinical PD research
3. Bioethics scholars fault requirement that all women in clinical drug trials use contraception
4. Clinical trial establishes catheter-based aortic valve replacement as new standard of care
5. New TB vaccine enters clinical testing
6. Aeras and Crucell announce Phase II clinical trial start in Kenya
7. First clinical trials successfully completed on potent new hepatitis C drug
8. Conference on the Future of Independent Academic Clinical Research in Europe
9. Preclinical inquiry into 1 mutation sheds light on addiction and a birth defect
10. CRF announces featured clinical trials to be presented at TCT 2010
11. Clinical trials: Comprehension unaffected by simplified consent forms or payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... years, Doctors on Liens has published a directory of the top doctors working ... When the company started in 1997, the directory was a single page focusing on chiropractors ... directory features a vast array of medical specialists stretching from Sacramento to San ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, ... standing as living proof that attitude and determination can combine into the most ... spike around the holidays. This campaign will offer patients a new-found hope, by ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research ... labeling, storing, shipping and disposal. The new version is a faster and a ...
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary ... included in the Emergency Response Training and Support Services ... excited to have LifeVac become part of the ERTSS ... Founder and CEO of LifeVac. "Having an established network ... and effectively will help leverage our efforts to spread ...
(Date:12/2/2016)... -- PipelineRx, a leading medication management technology company focused ... its SaaS-based telepharmacy platform, PowerGridRx™ , at ... Clinical Meeting and Exhibition, December 5-7 in ... hospital clients nationally, the Company is a leader ... improve pharmacy operations, enhance patient safety, and reduce ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: